PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the
treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and
other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary
hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to
normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial
and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain
threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in
patients at risk of developing cardiopulmonary disfunction after RT.